Telaprevir-based triple therapy outweighed risks for adverse events
Researchers reported that the treatment benefits associated with
telaprevir-based triple therapy for HCV offset any problems with adverse
events, and recommended the therapy for patients with advanced
In a prospective multicenter study, 102 patients with advanced fibrosis
who were infected with HCV genotype 1b received 12 weeks of telaprevir
(TVR) in combination with 24 weeks of pegylated interferon alfa-2b
(Peg-IFN a-2b) and ribavirin (RBV).